#Italy #CordenPharma #sterile injectables #Aseptic Manufacturing #Caponago

CordenPharma's Ambitious Expansion in Aseptic Manufacturing

CordenPharma, a prominent name in the contract development and manufacturing organization (CDMO) sector, is making waves with its latest investment aimed at significantly boosting its aseptic fill-finish capacity. With a long-term goal to produce 500 million sterile injectable units per year, the company is setting a new standard in the pharmaceutical industry with its expansion located at the FDA and EMA-approved facility in Caponago, Italy.

Unveiling the Investment

On September 10, 2026, CordenPharma revealed its ambition through a robust multi-year investment, totaling €80 million, designed to enhance the manufacturing landscape for sterile injectable drug products. At the heart of this expansion is the acquisition of a new 11,000 m² commercial facility together with an additional 26,000 m² of land adjacent to the current aseptic fill-finish area. This strategic move, finalized on July 28, 2026, increases the site’s footprint by over 50%, providing a significant boost to their operational capacity.

Expanding Capabilities for Future Needs

The expanded facility will serve as an ideal location for companies looking to outsource their aseptic fill-finish needs, particularly those developing peptide-based therapies, lipid nanoparticles (LNPs), and other complex modalities. The new space is designed to support various injectable formats, including Pre-Filled Syringes (PFS), vials (both liquid and lyophilized), and auto-injectors. With the flexibility to add up to four aseptic fill-finish lines and additional visual inspection and packaging lines, CordenPharma is positioning itself as a leader in meeting diverse client requirements.

Furthermore, the current operational area within the Caponago site has also undergone enhancements, including the addition of two aseptic fill-finish isolator lines. These new lines bolster manufacturing capabilities through:

• - A clinical and small-scale commercial combination line from Bausch Ströbel, catering to PFS, vials, and cartridges.
• - A high-speed assembly line from Syntegon designed to produce over 500,000 units per day.
• - An expanded automatic secondary packaging area that can handle various formats including PFS and ampoules.
• - A doubled capacity in their analytical capabilities, supporting growing project pipelines.

Scheduled for completion in 2027 and 2028 respectively, these additions will ensure that CordenPharma continues to lead in sterility assurance and compliance throughout the injectable manufacturing process.

Addressing Global Healthcare Needs

This substantial investment comes at a crucial time when the global healthcare industry faces a rising demand for specialized injectable manufacturing. With a projected production capability of up to 500 million injectable units per year, CordenPharma is set to support a wide array of therapeutic areas, such as oncology, diabetes, obesity, and inflammatory diseases. Notably, their expertise extends to complex modalities, integrating drug substance manufacturing with final product creation seamlessly within the same campus—a significant advantage for their clients.

CordenPharma’s CEO, Dr. Michael Quirmbach, expressed gratitude for the support from their shareholders, stating that this investment solidifies their leadership in the field and enhances their ability to respond to the increasing global demand for injectable therapeutics. The goal is to empower partners to deliver crucial drug products to patients more efficiently, ultimately enhancing patient care worldwide.

Conclusion

As CordenPharma advances its capabilities in sterile injectables, it signifies a transformative shift in the pharmaceutical manufacturing landscape. By prioritizing large-scale, compliant production environments tailored to modern therapeutic needs, CordenPharma is well-positioned to redefine industry standards and support the next generation of vital injectable drugs. For biotech and pharma innovators looking for a trustworthy partner in their drug development journey, CordenPharma stands out as a reliable ally, ready to tackle the most complex challenges in injectable therapeutics.

For more information, please visit CordenPharma’s official website.